Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 89

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 89
---
 (371,658 | ) |
| CASH FLOWS FROM FINANCING ACTIVITIES                                             |     |                  |          |   |     |                  |          |   |
| Increase (Decrease) in Convertible Notes Payable                                 |     |                  |        - |   |     |                  |  (10,000 | ) |
| Increase (Decrease) in Notes Payable                                             |     |                  |  168,655 |   |     |                  |  (61,500 | ) |
| Increase ( Decrease) in Common Stock issued for cash                             |     |                  |        - |   |     |                  |  400,234 |   |
| Net Cash Provided by (Used in) Financing Activities                              |     |                  |  168,655 |   |     |                  |  328,734 |   |
| Net Increase (Decrease) in Cash                                                  |     |                  |    1,045 |   |     |                  |  (42,924 | ) |
| Cash at Beginning of Period                                                      |     |                  |      716 |   |     |                  |  121,037 |   |
| Cash at End of Period                                                            |     | $                |    1,761 |   |     | $                |   78,114 |   |
| Supplemental Disclosure of Noncash investing and financing activities:           |     |                  |          |   |     |                  |          |   |
| Common shares Issued for Debt                                                    |     | $                |   20,000 |   |     | $                |        - |   |
| Preferred Shares Issued for Debt                                                 |     | $                |        - |   |     | $                |        - |   |
| Cash Paid for Interest                                                           |     | $                |        - |   |     | $                |        - |   |
| Common shares Issued for Interest                                                |     | $                |        - |   |     | $                |        - |   |
| Preferred Shares issued for Interest                                             |     | $                |        - |   |     | $                |        - |   |

The Accompanying Notes are an Integral Part of These Financial Statements

<div align='center'>69

REGEN BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

As of March 31, 2025</div>

These Notes have been retro